Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yishen Tiaojing Wan is a Traditional Chinese Medicine (TCM) formulation used primarily for treating gynecological conditions associated with kidney deficiency, such as irregular menstruation, diminished ovarian reserve (DOR), and infertility. Preclinical research indicates that the formula works by inhibiting the apoptosis of ovarian granulosa cells and improving overall ovarian function. Its mechanism of action involves the modulation of apoptotic pathways, specifically through the down-regulation of pro-apoptotic factors like caspase-3 and Bax, and the up-regulation of the anti-apoptotic protein Bcl-2. Furthermore, studies suggest it influences the PTEN/PI3K/AKT signaling pathway in ovarian tissues, which plays a critical role in follicle development and cell survival.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yishen Tiaojing Wan.